The review paper, Regorafenib for the Treatment of Sarcoma, was recently published in Current Treatment Options in Oncology, 23 (11):1477-1502 (2022).

We are pleased to share a snapshot of the paper in this video from Prof. Robert Maki, along with accompanying slides and an infographic summary of the findings.

Physicians face challenges in selecting the most appropriate and effective treatments for sarcomas. In this paper, experts summarise the unmet needs of this patient group and review the current trial data to examine the safety profile and clinical activity of regorafenib in sarcoma subtypes.

 

Clinical takeaways:

  • Regorafenib demonstrated benefit in patients with osteosarcoma, Ewing sarcoma and non-adipocytic soft tissue sarcomas who had progressed on prior therapy
  • Patients who have otherwise limited treatment options may benefit from regorafenib therapy

Dr Maki is a medical oncologist who has focused for over 20 years to understand tumors arising from connective tissues, which include sarcomas and other aggressive tumors that do not metastasize, such as desmoid tumors. These tumors represent less than 1% of all cancers that happen in adults. I work with patients with these diagnoses to find the right treatment for the 70 or more types of bone and soft tissue sarcomas and other soft tissue tumors. As part of this work, I also reserach new medications for cancer in general, a field called developmental therapeutics. In my research, I seek to find new medications that may be useful for sarcoma patients, and try to figure out why they work or not. I work closely with colleagues at Penn Medicine, the Children's Hospital of Philadelphia, and with other national and international teams of researchers such as SARC, the Sarcoma Alliance for Research through Collaboration, to improve the understanding and treatment of sarcomas.

Prof. Robert Maki has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

 American Society for Clinical Oncology,  Bayer, Deciphera, Kayopharm, Peel Therapeutics and Tracon.

Programme summary
Play the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
SARCOMA CONNECT

SARCOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Prostate cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resouces
  • clock 30 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Experts
Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
conference-update Conference update
Oncology 
GI highlights from ESMO 2023

An expert panel discussion hosted by COR2ED and eChinaHealth

  • clock 50 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from BeiGene Europe and SystImmune.
conference-update Conference update
Oncology 
RCC Update from ESMO 2023

How will the latest data impact clinical practice?

Experts
Prof. Laurence Albiges
  • download Downloadable
    Resouces
  • clock 4 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Eisai Europe Limited.
conference-update Conference update
Oncology 
Lung cancer highlights from ESMO 2023

An expert panel discussion hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
conference-update Conference update
Oncology 
Precision Oncology Update From ESMO 2023

How will the latest data impact clinical practice?

Experts
Dr Philipp Ivanyi
  • download Downloadable
    Resouces
  • clock 3 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Bayer.